Faeth Therapeutics, Inc.

FTH · Nasdaq · United States

Share price · FTH

$8.72-24.28 (-73.58%) 3M

close as of 2026-11-18 · 24h delayed · vol 332K (0.5x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when FTH's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 12 Nov 2026-20.2%
  2. 9 Nov 2026-42.5%
  3. 23 Oct 2026-15.0%
  4. 10 Aug 2026+17.1%
  5. 9 Jul 2026+16.1%

    Nothing announced by FTH that day or the session before.

  6. 22 Jun 2026+30.1%
  7. 12 Jun 2026+20.5%
  8. 2 Jun 2026-18.7%
  9. 29 May 2026+20.2%
  10. 19 May 2026-15.8%

Share of unusual movement by asset

For each asset, the share of FTH's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Serabelisib
events and moves
2shown from 8 days
Sapanisertib
events and moves
2shown from 8 days
Assets with fewer than 8 event days, together—3%
Other company news (earnings, financing, releases naming no asset)—58%
Sessions with no dated event—39%

Assets

(4 total)
4Total Assets
0Approved
0Phase 3 / Filed
4Phase 1–2 / Early
4Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
Phase 2
mTORC1/mTORC2 (dual inhibitor)Small molecule
Breast Cancer
HR+/HER2- Metastatic Breast Cancer
Phase 2
PI3K alpha (inhibitor)Small molecule
Breast CancerEndometrial Cancer
HR+/HER2- Metastatic Breast Cancer
Phase 1/2
VISTA (V-domain Ig suppressor of T-cell activation)Monoclonal antibody
Non-Small Cell Lung Cancer
Preclinical / Unstaged
—Small molecule
Colorectal Cancer

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
September 2028 (1)
Serabelisib + SapanisertibPhase 2Endometrial Cancer
Est. primary completion 2028-09 · NCT06463028 · CT.gov ↗
What to watch
2029 (1)
May 2029 (1)
Serabelisib + SapanisertibPhase 1/2HR+ HER2- Breast Cancer
Est. primary completion 2029-05 · NCT07558733 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3——$14M+ $161M short-term inv.$20M-$13M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2——$27M+ $160M short-term inv.$16M-$16M operating cash flowreport ↗
2026-Q1——$152M+ $50M short-term inv.$170M-$11M operating cash flowreport ↗
2025-Q3——$11M+ $14M short-term inv.$4.6M-$3.6M operating cash flowreport ↗
2025-Q2——$13M+ $16M short-term inv.$4.9M-$5.9M operating cash flowreport ↗
2025-Q1——$9.9M+ $24M short-term inv.$6.9M-$7.1M operating cash flowreport ↗
2024-Q3——$19M+ $28M short-term inv.$7.3M-$5.5M operating cash flowreport ↗
2024-Q2——$12M+ $40M short-term inv.$7.1M-$5.8M operating cash flowreport ↗
2024-Q1——$11M+ $47M short-term inv.$8.0M-$7.6M operating cash flowreport ↗
2023-Q3——$11M+ $61M short-term inv.$7.1M-$4.7M operating cash flowreport ↗
2023-Q2——$10M+ $69M short-term inv.$9.4M-$9.5M operating cash flowreport ↗
2023-Q1——$8.1M+ $87M short-term inv.$10M-$12M operating cash flowreport ↗
2022-Q3——$11M+ $105M short-term inv.$13M-$6.8M operating cash flowreport ↗
2022-Q2——$9.9M+ $114M short-term inv.$11M-$12M operating cash flowreport ↗
2022-Q1——$8.7M+ $128M short-term inv.$12M-$11M operating cash flowreport ↗
2021-Q3——$9.5M+ $147M short-term inv.$9.7M-$5.6M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY——$8.7M+ $13M short-term inv.$5.3M-$20M operating cash flowreport ↗

Faeth Therapeutics was acquired by Sensei Biotherapeutics, which reported full-year 2025 results with no revenue disclosed. R&D expenses were $11.0M versus $18.6M YoY, and cash and cash equivalents were $8.67M, while cash, cash equivalents and marketable securities totaled $21.2M, down from $41.3M YoY. Net loss was $21.1M, or $(16.72) per basic and diluted share, versus $30.2M, or $(24.01) per share, YoY, with quarterly net burn of $21.09M.

The Faeth acquisition added PIKTOR, an all-oral combination of serabelisib and sapanisertib targeting the PI3K/AKT/mTOR pathway, as Sensei’s lead program. A concurrent $200M private placement is expected, together with cash on hand, to support topline data from the ongoing Phase 2 endometrial cancer trial (FTH-PIK-201) and initiation of the planned Phase 1b HR+/HER2- advanced breast cancer trial (FTH-PIK-101), both expected by year-end 2026, with additional potential opportunities in ovarian and lung cancer. Sensei is also completing a Phase 1/2 trial of solnerstotug in advanced solid tumors.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY——$10.0M+ $31M short-term inv.$7.5M-$25M operating cash flowreport ↗
2023-FY——$13M+ $53M short-term inv.$8.5M-$32M operating cash flowreport ↗
2022-FY——$18M+ $89M short-term inv.$12M-$39M operating cash flowreport ↗
2021-FY——$7.2M+ $140M short-term inv.$9.2M-$30M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 49 purchases ($2.5M), 45 sales ($2.3M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-30Parikh Anand Kiran · director, President and CEOGift100,000——Form 4
2026-10-30Parikh Anand Kiran · director, President and CEOGift100,000——Form 4
2026-10-23Schayowitz Adam · directorAward / grant (derivative)25,000——Form 4
2026-09-11Vousden Karen H · directorAward / grant (derivative)25,000——Form 4
2026-07-21Parikh Anand Kiran · director, President and CEOAward / grant (derivative)398,018——Form 4
2026-07-21Craver Josiah · PAOAward / grant (derivative)30,824——Form 4
2026-07-01STEPHENSON BRIAN C · Chief Financial OfficerOpen-market purchase4,400$23.40$103KForm 4
2026-07-01STEPHENSON BRIAN C · Chief Financial OfficerOpen-market purchase600$24.22$15KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 30 reporting institutions held 2.3M shares ($70.3M, 8.9% of shares outstanding).

#InstitutionSharesValue
1Vivo Capital, LLC722,020$22.8M
2Cormorant Asset Management, LP306,222$9.7M
3STEMPOINT CAPITAL LP265,746$8.4M
4MILLENNIUM MANAGEMENT LLC146,565$4.6M
5FRANKLIN RESOURCES INC133,506$4.2M
6Caligan Partners LP126,002$4.0M
7Trails Edge Capital Partners, LP125,000$3.9M
8MARSHALL WACE, LLP65,730$2.1M
9GOLDMAN SACHS GROUP INC61,568$1.9M
10SUVRETTA CAPITAL MANAGEMENT, LLC34,549$1.1M
11BANK OF AMERICA CORP /DE/33,025$1.0M
12RENAISSANCE TECHNOLOGIES LLC32,041$1.0M
13Logos Global Management LP30,000$946K
14BOOTHBAY FUND MANAGEMENT, LLC26,124$823K
15Brevan Howard Capital Management LP20,333$641K